Feasibility of an Extended Test Battery and Influencing Factors for Detecting Frailty

October 7, 2020 updated by: Claudia Spies, Charite University, Berlin, Germany
The aim of the prospective study is to assess the feasibility of a screening and baseline measurement protocol that is planned for a main study (PRÄP-GO) in a collective of 30 patients ageing 70+ scheduled for elective surgery. Comprehensive geriatric assessment scores and modified Fried frailty phenotype component evaluation are performed in all patients at baseline before elective surgery. The assessment of cognitive tests is conducted with a battery of neuropsychological tests, computer-based tests from the Cambridge Neuropsychological Test Automated Battery [CANTAB®] and non-computer based tests. Frailty scores from 0 to 5 (i.e., 1 point for each component; 0 = best to 5 = worst) represent robust (0), pre-frail (1-2), and frail (3-5) health status. 10 patients without Frailty, 10 patients with Pre-Frailty and 10 patients with Frailty should be analyzed in this study and receive further comprehensive geriatric assessment testing up to seven days after surgery/discharge (before 7 postoperative days).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Germany
      • Berlin, Germany, 13353
        • Department of Anesthesiology and Operative Intensive Care Medicine (CCM/CVK), Charité - Universitätsmedizin Berlin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

70 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients undergoing elective surgery aged ≥70 years, including 10 patients without Frailty, 10 patients with Pre-Frailty and 10 patients with Frailty.

Description

Inclusion criteria:

  • Age ≥ 70 years
  • Male and female patients
  • Patient eligible for inclusion: by the patient, preoperatively
  • elective surgery
  • Expected anesthesia duration> 60min

Exclusion criteria:

  • Severe cardiological or pulmonary disease (NYHA IV, Gold IV)
  • Intracranial interventions
  • Moribund patients (palliative situation)
  • Not enough language skills
  • Non-consenting patients
  • Participation in another prospective intervention study for study inclusion or throughout the study period.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
10 non-frail (robust) study patients
Patients fulfill 0 criteria according to modified Fried frailty score.
10 pre-frail study patients
Patients fulfill 1-2 criteria criteria according to modified Fried frailty score.
10 frail study patients
Patients fulfill 3, 4 or 5 criteria according to modified Fried frailty score.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Duration to run the test battery
Time Frame: 1 day (Once only at screening)
The duration of the screening test battery is measured with a stopwatch.
1 day (Once only at screening)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Acceptance of test battery
Time Frame: 1 day (Once only at screening)
The study patient´s acceptance of the screening test battery is measured with a questionnaire.
1 day (Once only at screening)
Problems to conduct the test battery
Time Frame: 1 day (Once only at screening)
Problems while performing the test battery are categorized according to a standardized protocol.
1 day (Once only at screening)
Change in pain
Time Frame: Baseline, day 3 after surgery and discharge or day 7 after surgery
Pain is measured with a pain score, a higher score indicates more pain.
Baseline, day 3 after surgery and discharge or day 7 after surgery
Intelligibility of the patient Diary 1
Time Frame: Up to day 7 after surgery
Number of completed items
Up to day 7 after surgery
Intelligibility of the patient Diary 2
Time Frame: Up to day 7 after surgery
Number of completed days
Up to day 7 after surgery
Intelligibility of the patient Diary 3
Time Frame: Up to day 7 after surgery
Coherence of the diary with clinical patient record
Up to day 7 after surgery
Implementation rate of the patient Diary 3
Time Frame: Up to day 7 after surgery
Up to day 7 after surgery
Handgrip strength
Time Frame: Baseline, day 3 after surgery and discharge or day 7 after surgery
Handgrip strength measured using a Dynamometer.
Baseline, day 3 after surgery and discharge or day 7 after surgery
Mobility
Time Frame: Baseline, day 3 after the operation and discharge or day 7 after surgery
Mobility is measured using the Charité Mobilitäts-Index (CHARMI®).
Baseline, day 3 after the operation and discharge or day 7 after surgery
Nutritional status 1
Time Frame: Baseline and discharge or day 7 after surgery
Nutritional status 1 is measured using serum albumin.
Baseline and discharge or day 7 after surgery
Nutritional status 2
Time Frame: Baseline and discharge or day 7 after surgery
Nutritional status 2 is measured using arm circumference.
Baseline and discharge or day 7 after surgery
Nutritional status 3
Time Frame: Baseline and discharge or day 7 after surgery
Nutritional status 3 is measured using calf circumference.
Baseline and discharge or day 7 after surgery
Nutritional status 4
Time Frame: Baseline and discharge or day 7 after surgery
Nutritional status 4 is measured using the Mini Nutritional Assessment - Short Form (MNA®-SF).
Baseline and discharge or day 7 after surgery
Intra- and postoperative organ complications
Time Frame: Up to 7 days after surgery
Up to 7 days after surgery
Length of intensive care unit stay
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day.
Participants will be followed for the duration of hospital stay, an expected average of 1 day.
Length of stay
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 7 days.
Participants will be followed for the duration of hospital stay, an expected average of 7 days.

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Cognitive Status
Time Frame: 1 day (Once only at screening)
Neuropsychological testing
1 day (Once only at screening)
Depression
Time Frame: 1 day (Once only at screening)
The assessment of Depression is measured with the - Patient Health Questionnaire (PHQ-8)
1 day (Once only at screening)
Frailty
Time Frame: 1 day (Once only at screening)
Frailty is operationalized using modified Fried frailty criteria. Frailty scores from 0 to 5 (i.e., 1 point for each component; 0 = best to 5 = worst) represent robust (0), pre-frail (1-2), and frail (3-5) health status.
1 day (Once only at screening)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Charite University, Berlin, Germany

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Claudia Spies, MD Prof., Department of Anesthesiology and Operative Intensive Care Medicine (CCM/CVK), Charité Univerisitätsmedizin Berlin

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 18, 2019

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 16, 2020

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 20, 2020

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 28, 2019

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 4, 2019

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 9, 2019

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 8, 2020

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 7, 2020

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Frailty-Testing

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings